Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 45 Products per page

Inhalation Drug Delivery Devices Market

$4,750.00

The combined prevalence of asthma and COPD in the countries covered by this report (US, Japan, and five major EU markets of France, Germany, Italy, Spain, and the UK) is 109.3 million. The combined market for inhalation drug delivery devices totaled nearly $11.7bn in 2016, and is expected to climb at a rate of 1.2% over the forecast period. Generic erosion will be a key factor in limiting growth in the overall market; however, increasing disease prevalence and the introduction of novel products such as triple combination therapies will offset declines. The US accounts for nearly two-thirds of the overall inhalation drug delivery devices market, and is expected to experience the most growth over the forecast period as its population increases and ages.
July 19, 2017
Find out more
Company Analysis: Novo Nordisk

$3,000.00

PharmaVitae explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Bevespi Aerosphere
Read More
Bevespi Aerosphere ([formoterol + glycopyrrolate]; AstraZeneca) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist (LABA) formoterol and the long-acting muscarinic antagonist (LAMA) glycopyrrolate, delivered via a pressurized metered dose inhaler.
July 31, 2018
Find out more
Global Markets for Infection Control and Biosafety Products, October 2016

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global medical waste disposal, device reprocessing, standard and safety needle/syringe, sharps disposal, and sterilization equipment and services markets.
October 7, 2016
Find out more
Cilofexor
Read More
Cilofexor (Gilead), a nonsteroidal FXR agonist, is a ligand-activated nuclear hormone receptor that is a key regulator of bile acid synthesis, conjugation, and excretion. It is abundant in the liver, gallbladder, intestines, and kidney. Stimulation of FXR in the intestine by bile acids or an FXR agonist results in the release of fibroblast growth factor 19 (FGF19).
July 22, 2019
Find out more
Lu AF35700
Read More
Lu AF35700 (Lundbeck) has a novel pharmacological profile as a dopamine D1 and D2 antagonist with a high occupancy of 5-HT2A and 5-HT6 serotonin receptors.
March 19, 2018
Find out more
Epidiolex
Read More
GW Pharmaceuticals is developing Epidiolex, a first-in-class cannabinoid drug for the treatment of

childhood seizures.
May 23, 2017
Find out more
Aurora-GT
Read More
United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells)
October 29, 2018
Find out more
INOpulse
Read More
INOpulse (Bellerophon Therapeutics) is a drug-device combination being developed to deliver a continuous, pulsed dose of nitric oxide via intranasal inhalation.
October 29, 2018
Find out more
Zeftera
Read More
Zeftera (ceftobiprole medocaril; Basilea Pharmaceutica) is a novel intravenous broad-spectrum fifth-generation cephalosporin.
June 19, 2015
Find out more
UK Healthcare System Overview

$2,995.00

Reform of the NHS is underway despite widespread controversy and opposition from physicians, and will necessitate a change in the way pharmaceutical companies work with key stakeholders.
November 2, 2016
Find out more
Orthobiologics for Bone Repair and Regeneration

$4,750.00

Sales of orthobiologics for the repair and regeneration of bone totaled nearly $2.4bn in 2018, with sales expected to climb at a CAGR of 3.2% through 2024. Growth in this market will be driven by the aging of the population and the global burden of musculoskeletal disease.
March 5, 2020
Find out more
HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.
August 10, 2021
Find out more
Fluzone High-Dose
Read More
Fluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
2015 Breast Cancer Pulse #1

$599.00

This five-question survey of oncologists focuses on treatments for metastatic or locally advanced, HR+/HER2- breast cancer.
May 13, 2015
Find out more
Isentress
Read More
Isentress (raltegravir; Merck & Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.
June 28, 2019
Find out more
Xadago
Read More
Xadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible inhibition of monoamine oxidase B (MAO-B) and inhibition of excessive glutamate release by blocking the activity of the voltage-dependent sodium channels.
June 21, 2018
Find out more
Drug Delivery: Inhalation Devices

$4,750.00

This Meddevicetracker report includes a discussion of inhalation devices, products, current/forecast markets, competitors, and opportunities in the global markets for inhalation-based drug delivery devices for the treatment of asthma and COPD and much more.
December 14, 2021
Find out more
Duopa
Read More
AbbVie’s Duopa, a continuous intestinal infusion of a carbidopa plus levodopa gel, is indicated for the treatment of advanced-stage idiopathic Parkinson’s disease with motor fluctuations that cannot be treated with oral therapies.
June 21, 2018
Find out more
Market Spotlight: Acne

$1,318.00

This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Allergan

$3,000.00

PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 10, 2018
Find out more
Neuromodulation KOL Interview

$599.00

Neuromodulation KOL Interview

February 5, 2015
Find out more
Market Spotlight: Huntington’s Disease

$1,318.00

This Market Spotlight report covers the Huntington’s Disease market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
July 19, 2022
Find out more
Lonsurf
Read More
Lonsurf ([trifluridine + tipiracil]; Otsuka/Servier) is an oral combination drug with both anti-angiogenic and cytotoxic effects.
December 11, 2017
Find out more
Orphan Drug Market Outlook to 2017

$3,000.00

Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.
September 28, 2016
Find out more
Post-AAIC KOL Interview

$599.00

Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.
August 6, 2014
Find out more
TS-1
Read More
TS-1 (Otsuka/Nordic Group) is an orally available cytotoxic drug that contains gimeracil, oteracil potassium, and tegafur as active ingredients.
December 11, 2017
Find out more
Sutent
Read More
Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3.
March 6, 2019
Find out more
Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.
November 18, 2021
Find out more
Seizure Pulse Survey

$599.00

Eslicarbazepine has been approved in ex-US markets including the EU for years.

We surveyed 10 US Neurologists to determine prelaunch perceptions of Aptiom.
March 25, 2014
Find out more
Orencia
Read More
Orencia (abatacept; Bristol-Myers Squibb/Ono Pharmaceutical) is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte antigen-4.
October 17, 2017
Find out more
Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)

$1,318.00

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
August 2, 2022
Find out more
Thalomid
Read More
Thalomid contains thalidomide, a glutamic acid derivative that possesses immunomodulatory, antiinflammatory,
and anti-angiogenic properties.
August 9, 2018
Find out more
Ularitide
Read More
Ularitide’s (Cardiorentis) favorable results in its pivotal Phase III trial could be a key driver of uptake,

especially as Natrecor (nesiritide; Johnson & Johnson), its major marketed competitor, failed to show

added clinical value and benefit on survival.
March 16, 2016
Find out more
Human Papillomavirus (HPV) KOL Interview – US, Midwest

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.
January 3, 2020
Find out more
Pulmonary Hypertension KOL Interview – Germany

$599.00

This interview with a Germany-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, INOpulse, and sotatercept.
July 21, 2022
Find out more
Prostate Cancer KOL Interview – UK #1

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.
February 9, 2022
Find out more
U.S. Markets for Cardiac Rhythm Management Products, February 2015

$4,750.00

Cardiac rhythm management (CRM) devices, which encompasses diagnostic and therapeutic systems, represents a well-established market that is still seeing innovation in some of the segments that compose it.
February 2, 2015
Find out more
Azeliragon
Read More
Azeliragon is an orally available small molecule that acts as an inhibitor of the receptor for advanced glycation endproducts (RAGE).
September 2, 2016
Find out more
MOR208
Read More
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant.
October 9, 2018
Find out more
Stiolto Respimat
Read More
Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim) is a fixed-dose combination of the long-acting beta 2 agonist (LABA) olodaterol and the gold-standard long-acting muscarinic antagonist (LAMA) tiotropium.
July 31, 2018
Find out more
Afstyla
Read More
Afstyla is a single-chain recombinant factor VIII (rfVIII) product developed by CSL Behring to have a longer duration of action than standard rfVIII. Endogenously produced fVIII consists of a light chain and a heavy chain fused via a metal ion bridge.
May 4, 2018
Find out more
Vigil
Read More
Vigil (Gradalis) is an autologous tumor-based vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a novel.
October 30, 2015
Find out more
Asciminib
Read More
Asciminib (Novartis) is a BCR-ABL-targeted tyrosine kinase inhibitor (TKI) in development by Novartis for Philadelphia chromosome-positive diseases such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia.
December 7, 2017
Find out more
U.S. Markets for Neurosurgical and Neurointerventional Products

$3,750.00

This dynamic, new report from Medtech Insight includes analyses of selected products, current/forecast markets, surgical procedure volumes, competitors, market share by supplier, and opportunities in the U.S. Neurosurgical and Neurointerventional Products Market.
September 22, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *